Results 11 to 20 of about 33,833 (238)

Safety of prolonged treatment with bedaquiline in programmatic conditions

ERJ Open Research, 2022
Bedaquiline is now considered a first-line medicine for treatment of rifampicin-resistant tuberculosis (RR-TB). We evaluated the safety of treatment with bedaquiline for longer than 190 days in individuals with RR-TB under programmatic conditions.
Dzmitriy Zhurkin, Elmira Gurbanova, Jonathon R. Campbell, Dick Menzies, Svetlana Setkina, Hennadz Hurevich, Varvara Solodovnikova, Dzmitry Viatushka, Alan Altraja, Alena Skrahina   +9 more
doaj   +1 more source

Safety, efficacy, and serum concentration monitoring of bedaquiline in Chinese patients with multidrug-resistant tuberculosis

International Journal of Infectious Diseases, 2021
Objectives: To determine the safety and efficacy of bedaquiline for Chinese patients with multidrug-resistant tuberculosis (MDR-TB) based on serum concentration monitoring and to identify factors associated with QTc prolongation occurring during ...
Jinmeng Li, Gaoyi Yang, Qingshan Cai, Yu Wang, Yingying Xu, Ruoying Zhang, Yazhen Lang, Xinjun Cai   +7 more
doaj   +1 more source

A prospective patient registry to monitor safety, effectiveness, and utilisation of bedaquiline in patients with multidrug-resistant tuberculosis in South Korea

BMC Infectious Diseases, 2023
Background Multidrug-resistant tuberculosis (MDR-TB) represents a major public health concern, with an ongoing need for new effective treatments. Bedaquiline is an oral diarylquinoline that has shown encouraging treatment success and culture conversion ...
Tae Sun Shim, Helen Pai, JeongHa Mok, Seung Heon Lee, Yong-Soo Kwon, Jae Chol Choi, JaeSeok Park, Eileen Birmingham, Gary Mao, Lori Alquier, Kourtney Davis, Florence Thoret-Bauchet, Ji Hyun Kim, Hyeongyeong Kim, Nyasha Bakare   +14 more
doaj   +1 more source

Tolerability and Efficacy of Chemotherapy Containing Bedaquiline in Patients with Multiple Drug Resistant Pulmonary Tuberculosis

Туберкулез и болезни лёгких, 2022
The objective: to evaluate safety and efficacy of bedaquiline in the treatment of patients with multiple drug resistant tuberculosis (MDR-TB).Subjects and Methods.
O. V. Filinyuk, D. Yu. Schegertsov, N. N. Kabanets, D. E. Amichba   +3 more
doaj   +1 more source

Molecular characteristics and in vitro susceptibility to bedaquiline of Mycobacterium tuberculosis isolates circulating in Shaanxi, China

International Journal of Infectious Diseases, 2020
Objective: The aim of this study was to investigate the molecular characteristics and in vitro susceptibility to bedaquiline of Mycobacterium tuberculosis (MTB) isolates from Shaanxi, China.
Jian Yang, Yu Pang, Tianhua Zhang, Xiaoping Xian, Yan Li, Rui Wang, Panting Wang, Meng Zhang, Junyang Wang   +8 more
doaj   +1 more source

Bedaquiline, pretomanid and linezolid for treatment of extensively drug resistant, intolerant or non-responsive multidrug resistant pulmonary tuberculosis

New England Journal of Medicine, 2020
Background Patients with extensively drug resistant tuberculosis (TB) have limited treatment options with historically poor outcomes. We investigated treatment with 3 oral drugs, bedaquiline (B), pretomanid (Pa) and linezolid (L), (B-Pa-L), with TB ...
F. Conradie, A. Diacon, N. Ngubane, P. Howell, D. Everitt, A. Crook, C. Mendel, E. Egizi, Joanna Moreira, J. Timm, T. McHugh, G. Wills, A. Bateson, R. Hunt, C. van Niekerk, Mengchun Li, M. Olugbosi, M. Spigelman   +17 more
semanticscholar   +1 more source

Submission for Special Issue: The Role of Platelet Activation in the Pathophysiology of HIV, Tuberculosis, and Pneumococcal Disease. Bedaquiline Suppresses ADP-Mediated Activation of Human Platelets In Vitro via Interference With Phosphatidylinositol 3-Kinase

Frontiers in Immunology, 2021
Although bedaquiline has advanced the treatment of multidrug-resistant tuberculosis (TB), concerns remain about the cardiotoxic potential of this agent, albeit by unexplored mechanisms.
Gregory R. Tintinger, Annette J. Theron, Helen C. Steel, Moloko C. Cholo, Jan G. Nel, Jan G. Nel, Charles Feldman, Ronald Anderson   +7 more
doaj   +1 more source

GRADE Evidence to Decision (EtD) frameworks : A systematic and transparent approach to making well-informed healthcare choices. 1. Introduction [PDF]

, 2016
Funding: Work on this article has been partially funded by the European Commission FP7 Program (grant agreement 258583) as part of the DECIDE project. Sole responsibility lies with the authors; the European Commission is not responsible for any use that ...
Akl, Elie A., Alonso-Coello, Pablo, Brignardello-Petersen, Romina, Davoli, Marina, Guyatt, Gordon H., Moberg, Jenny, Morelli, Angela, Mustafa, Reem A., Oxman, Andrew D., Rada, Gabriel, Rosenbaum, Sarah, Schünemann, Holger J., the GRADE Working Group, Treweek, Shaun   +13 more
core   +1 more source

Comparative safety of bedaquiline and delamanid in patients with multidrug resistant tuberculosis: A nationwide retrospective cohort study

Journal of Microbiology, Immunology and Infection, 2023
Background/Purpose(s): Bedaquiline and delamanid were recently approved for multidrug resistant tuberculosis (MDR-TB). Bedaquiline carries a black box warning of increased risk of death compared to the placebo arm, and there is a need to establish the ...
Ju Hwan Kim, Hyesung Lee, In-Sun Oh, Han Eol Jeong, Sungho Bea, Seung Hun Jang, Hyunjin Son, Ju-Young Shin   +7 more
doaj   +1 more source

Structural Simplification of Bedaquiline: the Discovery of 3-(4-(N,N-dimethylaminomethyl)phenyl)quinoline Derived Antitubercular Lead Compounds [PDF]

, 2016
Bedaquiline (BDQ) is a novel and highly potent last-line antituberculosis drug that was approved by the US FDA in 2013. Owing to its stereo-structural complexity, chemical synthesis and compound optimization are rather difficult and expensive. This study
Cui, HC, Fu, LF, He, CH, Meier, TK, Preiss, LP, Wang, BW, Wen, HW, Yin, DY, Zhang, XZ   +8 more
core   +1 more source